Abstract

Piwi-interacting RNAs (piRNAs) represent a novel class of small non-coding RNAs (ncRNAs) that have been shown to have a deregulated expression in several cancers, although their clinical significance in colorectal cancer (CRC) remains unclear. With an aim of delineating the piRNA distribution in CRC, we conducted a systematic discovery and validation of piRNAs within two clinical cohorts. In the discovery phase, we profiled tumor and adjacent normal tissues from 18 CRC patients by deep sequencing and identified a global piRNA downregulation in CRC. Moreover, we identified piR-24000 as an unexplored piRNA that was significantly overexpressed in CRC. Using qPCR, we validated the overexpression of piR-24000 in 87 CRC patients. Additionally, we identified a significant association between a high expression of piR-24000 and an aggressive CRC phenotype including poor differentiation, presence of distant metastases, and a higher stage. Lastly, ROC analysis demonstrated a strong diagnostic power of piR-24000 in discriminating CRC patients from normal subjects. Taken together, this study provides one of the earliest large-scale reports of the global distribution of piRNAs in CRC. In addition, piR-24000 was identified as a likely oncogene in CRC that can serve as a biomarker or a therapeutic target.

Highlights

  • Colorectal cancer (CRC) is responsible for 10.2% of all new cancer cases, while being the second leading cause for cancer-related deaths worldwide [1]

  • Our study provides the first report that Piwi-interacting RNAs (piRNAs) are strongly dysregulated in colorectal cancer (CRC) as compared to the adjacent non-malignant tissues

  • We provided systematic evidence to show that piR-24000 is frequently upregulated in CRC, in patients presenting with an aggressive phenotype including poor tumor differentiation, advanced stage, and presence of distant metastasis

Read more

Summary

Introduction

Colorectal cancer (CRC) is responsible for 10.2% of all new cancer cases, while being the second leading cause for cancer-related deaths worldwide [1]. Via a better understanding of the molecular networks surrounding the growth, development, and spread of CRC can we identify effective therapeutic avenues to circumvent the issues associated with poor prognosis. There is mounting evidence to indicate a crucial role of epigenetic alterations in the pathogenesis of CRC [8,9,10,11,12]. The role of non-coding RNAs (ncRNAs) as critical epigenetic regulators responsible for the occurrence and Cancers 2020, 12, 188; doi:10.3390/cancers12010188 www.mdpi.com/journal/cancers

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call